Target / Biomarker
Discovery & Validation
Euretos is an AI (Artificial Intelligence) platform used by pre-clinical researchers for in-silico discovery & validation of targets and biomarkers. World leading pharma, biotech and academic institutions use it to accelerate their research. Available as subscription, consulting service or direct access
EURETOS AI PLATFORM
In Silico Multi Omics
Drive your in vitro and in vivo research by in silico multi omics analysis. Ask Euretos and evaluate how molecular mechanisms influence cell and tissue functions, and in turn mediate phenotypes and disease pathology.
FIND OUT MORE
Euretos Announces the Addition of Leland Johnson as Business Development Director for the US East Coast and Eastern CanadaTuesday 13 March 2018
Boston, MA and Zoetermeer, NL [March 13, 2018]Euretos, the leader in the area of in silico discovery and validation of targets and biomarkers, announces the addition of Leland Johnson to the sales team. Based in Boston, Massachusetts, Mr. Johnson w ...
Euretos AI Platform predicts key molecular mechanism for recently identified lung cancer targetThursday 22 February 2018
In a recent study, published in the Oncotarget journal, researchers identified PRC1 as a novel potential target for lung cancer. The study found that tumorigenesis and cell proliferation strongly depend on PRC1 and inhibition of PRC1 significantly ...
Prof David Webb (The Scripps Research Institute)
“The Euretos AI Platform is nothing less than an in silico way to save all drug and biotech researchers an infinite amount of blood, sweat and tears by providing
them with a powerful knowledge discovery platform.
The Euretos AI Platform allows the researcher to rapidly assess whether a given target, research area, etc., is related, even distantly, to another such entity thus allowing one to uncover hidden connections, leading to new knowledge.In the drug discovery arena, this thing is a gold mine.